EPL Announces Second Quarter 2008 Results StreetInsider.com (subscription), MI - Aug 5, 2008 The conference call will be webcast live as well as for on-demand listening at the Company's web site, www.eplweb.com. Listeners may access the call through ...EPL - NBL
Source: Google News
[PDF]TREC2001 Question-Answer, Web and Cross Language experiments using PIRCS - KL Kwok, L Grunfeld, N Dinstl, M Chan - Proceedings of the TREC-10 Conference, 2001 - scils.rutgers.edu ... what unit 29 0.24 0.21 0.24 0.26 7% ... The target collection for the Web track is the
W10g disks used last year. ... 0 .2160 3 .2780 11 P@20 .2070 0 .2110 4 .2370 15 P ... -
A protein?protein docking benchmark - R Chen, J Mintseris, J Janin, Z Weng - Proteins, 2003 - doi.wiley.com ... 7NN9 Fab NC10 Influenza virus neuraminidase 0.21 0 1350 ... Thrombin mutant Pancreatic
trypsin inhibitor 1.91 18 2370... benchmark is available from the web site http ...
Small-Diameter Silicon Nanowire Surfaces - DDD Ma, CS Lee, FCK Au, SY Tong, ST Lee - Science, 2003 - sciencemag.org ... you are using a browser that does not support current Web standards. ... the HH distance
on the neighboring Si atoms is 0.21 nm (14 ... 67, 2370 (1995) [CrossRef] [ISI ...
Heavy metals in soils near the nickel smelter: chemistry, spatial variation, and impacts on plant … - S Koptsik, G Koptsik, S Livantsova, L Eruslankina, … - Journal of Environmental Monitoring, 2003 - xlink.rsc.org ... First published on the web 19th March 2003. ... 46, 34.6, 14.5, 21, 2.45, 0.98, 0.71,
11, 3.2, 109, 2370, 1060, 57. ... Std, 0.17, 0.54, 0.52, 5.0, 3.2, 2.9, 5.2, 0.50, 0.21... -
Source: Google Scholar
Efficacy of Revlimid in patients with myelofibrosis
A Phase II study evaluated Revlimid ( Lenalidomide ) in previously treated patients with myelofibrosis, a rare blood disorder that can be fatal if untreated.
Clinical data were reported during the 47th American Society of Hematology ( ASH ) Meeting in Atlanta.
Myelofibrosis ( also called agnogenic myeloid metaplasia ) is a myeloproliferative disorder in which the bone marrow is initially over-active but then develops fibrosis.
The study, lead investigator Jorge Cortez, of the University of Texas, M.D. Anderson Cancer Center, Houston, enrolled forty-one patients with myelofibrosis, primary or associated with myeloproliferative disorders, with a platelet count of at least 30x10(9)/L.
The patients with a median age of 65 ( range, 42 to 83 ) received Lenalidomide at 10 mg/day orally ( 5 mg daily for patients with a platelet count less than 100,000 at the start of the study ).
Patients may have received prior therapies, but were excluded if they had known hypersensitivity to Thalidomide.
Thirty-six patients ( 88% ) had received prior therapy for myelofibrosis , including thirteen Thalidomide patients ( 32% ), thirteen Hydroxyurea patients ( 32% ), eleven Interferon patients ( 27% ), ten Anagrelide patients ( 24% ), and six Erythropoietin patients ( 15% ).
Thirty-two patients were evaluable for response or toxicity.
Responses were observed in nineteen patients ( 46% ), including complete response ( CR ) achieved in three patients defined by normalization of Hgb and WBC, respectively.
Partial response ( PR ) was achieved in five patients as a result of improvement in platelets and Hgb, +/- spleen, and hematologic improvement was observed in eleven patients based on improvement in platelets, spleen, WBC and BM blasts.
Five of thirteen transfusion-dependent patients became transfusion independent.
The median time to response was six weeks ( range, 1 to 22 ). Responses were sustained for a median of thirty-one weeks ( range, 1 to 40 weeks ).
Therapy was well tolerated and side-effects clinically manageable, with the more common toxicities being rash in sixteen patients ( 39% ), pruritus in nine patients ( 22% ), thrombocytopenia in eleven patients ( 29% ), fatigue in three patients ( 7% ), and neutropenias in thirteen patients ( 32% ).
Eight patients ( 20% ) have required dose reduction and four discontinued therapy because of toxicity.
